Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication

American Journal of Cardiology

Volumn 90, Issue 5, 2002, Pages 512-516

  Rajagopalan, Sanjay ^a,h   Trachtenberg, Jeffrey ^b   Mohler, Emile ^c   Olin, Jeffrey ^d   McBride, Scott ^e   Pak, Raphael ^e   Rasmussen, Henrik ^f   Crystal, Ronald ^g  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Heart and Vascular Institute of New Jersey   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e PFIZER INC   (United States)

^f GENVEC INC   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CL 1023; COMPLEMENTARY DNA; PLACEBO; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANALYTICAL PARAMETERS; ANGIOGRAPHY; ARTICLE; BYPASS SURGERY; CLAUDICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FOLLOW UP; GENE THERAPY; HUMAN; HYPERSENSITIVITY REACTION; INGUINAL REGION; MALE; PARAMETER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TIME; VIRUS REPLICATION; WALKING;

ADENOVIRIDAE; ADULT; AGED; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIAL GROWTH FACTORS; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; GENETIC VECTORS; HUMANS; IMMUNE SYSTEM; INTERMITTENT CLAUDICATION; LYMPHOKINES; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VIRUS REPLICATION; WALKING;

EID: 0036710990     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02524-9     Document Type: Article

References (20)

1. Isner J.M., Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 103:1999;1231-1236.
2. Bauters C., Asahara T., Zheng L.P., Takeshita S., Bunting S., Ferrara N., Symes J.F., Isner J.M. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol Heart Circ Physiol. 267:1994;H1263-H1271.
3. Takeshita S., Zheng L.P., Brogi E., Kearney M., Pu L.Q., Bunting S., Ferrara N., Symes J.F., Isner J.M. Therapeutic angiogenesis A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model . J Clin Invest. 93:1994;662-670.
4. Tsurumi Y., Takeshita S., Chen D., Kearney M., Rossow S.T., Passeri J., Horowitz J.R., Symes J.F., Isner J.M. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation. 94:1996;3281-3290.
5. Horowitz J.R., Rivard A., van der Zee R., Hariawala M., Sheriff D.D., Esakof D.D., Chaudhry G.M., Symes J.F., Isner J.M. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension Evidence for a maintenance role in quiescent adult endothelium . Arterioscler Thromb Vasc Biol. 17:1997;2793-2800.
6. Henry T. Final results for the VIVA trial of rhVEGF for human therapeutic angiogenesis (abstr). Circulation. 100:1999;A2509.
7. Simons M., Annex B.H., Laham R.J., Kleiman N., Henry T., Dauerman H., Udelson J.E., Gervino E.V., Pike M., Whitehouse M.J., Moon T., Chronos N.A. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 105:2002;788-793.
8. Isner J.M., Pieczek A., Schainfeld R., Blair R., Haley L., Asahara T., Rosenfield K., Razvi S., Walsh K., Symes J.F. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 348:1996;370-374.
9. Baumgartner I., Pieczek A., Manor O., Blair R., Kearney M., Walsh K., Isner J.M. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 97:1998;1114-1123.
10. 121.10) in patients with peripheral vascular disease (abstr). Circulation. 104:2001;A262.
11. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy. 6:1999;1574-1583.
12. Baumgartner I., Rauh G., Pieczek A., Wuensch D., Magner M., Kearney M., Schainfeld R., Isner J.M. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med. 132:2000;880-884.
13. Isner J.M., Vale P.R., Symes J.F., Losordo D.W. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circulation Res. 89:2001;389-400.
14. Montie J., Smith D., Sandler H. Bladder carcinoma. Abeloff M., Clinical Oncology. 2002.
15. Zoltick P.W., Chirmule N., Schnell M.A., Gao G.P., Hughes J.V., Wilson J.M. Biology of E1-deleted adenovirus vectors in nonhuman primate muscle. J Virol. 75:2001;5222-5229.
16. Molnar-Kimber K.L., Sterman D.H., Chang M., Kang E.H., ElBash M., Lanuti M., Elshami A., Gelfand K., Wilson J.M., Kaiser L.R., Albelda S.M. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Human Gene Therapy. 9:1998;2121-2133.
17. Money S.R., Herd J.A., Isaacsohn J.L., Davidson M., Cutler B., Heckman J., Forbes W.P. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 27:1998;267-274.
18. Brevetti G., Diehm C., Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol. 34:1999;1618-1624.
19. Dawson D.L., Cutler B.S., Meissner M.H., Strandness D.E. Jr. Cilostazol has beneficial effects in treatment of intermittent claudication results from a multicenter, randomized, prospective, double-blind trial . Circulation. 98:1998;678-686.
20. Lederman R.J., Tenaglia A.N., Anderson D., Hermiller A.N., Anderson D., Rocha-Singh K., Mendelsohn F.O., Hiatt W.R., Moon T., Whitehouse M.J., Annex B.H. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial. Lancet. 359:2002;2053-2058.